KPC Pharmaceuticals,Inc. (SHA:600422)
China
· Delayed Price · Currency is CNY 12.15
-0.01 (-0.08%)
Mar 10, 2026, 3:00 PM CST
KPC Pharmaceuticals,Inc. Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 6,577 | 7,960 | 8,266 | 7,720 | 8,045 | Upgrade
|
| Other Revenue | - | 441.93 | 163.98 | 562.24 | 208.77 | Upgrade
|
| Revenue | 6,577 | 8,401 | 8,430 | 8,282 | 8,254 | Upgrade
|
| Revenue Growth (YoY) | -21.72% | -0.34% | 1.79% | 0.35% | 6.95% | Upgrade
|
| Cost of Revenue | 6,128 | 4,771 | 4,544 | 4,855 | 4,865 | Upgrade
|
| Gross Profit | 448.51 | 3,631 | 3,886 | 3,427 | 3,389 | Upgrade
|
| Selling, General & Admin | - | 2,597 | 2,983 | 2,812 | 2,779 | Upgrade
|
| Research & Development | - | 106.76 | 94.2 | 69.65 | 100.52 | Upgrade
|
| Other Operating Expenses | - | 81.5 | 84.64 | -57.25 | 64.56 | Upgrade
|
| Operating Expenses | - | 2,831 | 3,206 | 2,864 | 2,980 | Upgrade
|
| Operating Income | 448.51 | 800.18 | 679.83 | 563.54 | 409.19 | Upgrade
|
| Interest Expense | - | -26.36 | -21.61 | -40.73 | -33.59 | Upgrade
|
| Interest & Investment Income | - | 27.78 | 38.14 | 12.05 | 156.1 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 1.92 | 2.08 | 3.08 | -3.48 | Upgrade
|
| Other Non Operating Income (Expenses) | 25.05 | 13.16 | 7.55 | -27.97 | -7.25 | Upgrade
|
| EBT Excluding Unusual Items | 473.56 | 816.67 | 705.99 | 509.97 | 520.97 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 6.92 | 1.03 | 10.67 | -0.96 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 1.01 | 1.04 | 15.21 | 2.2 | Upgrade
|
| Asset Writedown | - | -2.04 | -30.12 | -57.73 | -0.29 | Upgrade
|
| Other Unusual Items | - | 112.01 | 108.45 | -0.84 | 109.37 | Upgrade
|
| Pretax Income | 473.56 | 934.57 | 786.38 | 477.29 | 631.29 | Upgrade
|
| Income Tax Expense | 123.62 | 183.35 | 143.7 | 91.83 | 118.07 | Upgrade
|
| Earnings From Continuing Operations | 349.94 | 751.22 | 642.67 | 385.46 | 513.21 | Upgrade
|
| Minority Interest in Earnings | - | -103.14 | -101.96 | -2.28 | -5.55 | Upgrade
|
| Net Income | 349.94 | 648.08 | 540.71 | 383.18 | 507.67 | Upgrade
|
| Net Income to Common | 349.94 | 648.08 | 540.71 | 383.18 | 507.67 | Upgrade
|
| Net Income Growth | -46.00% | 19.86% | 41.11% | -24.52% | 11.12% | Upgrade
|
| Shares Outstanding (Basic) | 761 | 754 | 762 | 751 | 758 | Upgrade
|
| Shares Outstanding (Diluted) | 761 | 754 | 762 | 751 | 758 | Upgrade
|
| Shares Change (YoY) | 0.95% | -1.05% | 1.36% | -0.84% | -0.19% | Upgrade
|
| EPS (Basic) | 0.46 | 0.86 | 0.71 | 0.51 | 0.67 | Upgrade
|
| EPS (Diluted) | 0.46 | 0.86 | 0.71 | 0.51 | 0.67 | Upgrade
|
| EPS Growth | -46.51% | 21.13% | 39.22% | -23.88% | 11.33% | Upgrade
|
| Free Cash Flow | - | 728.63 | 644.69 | 152.15 | 15.46 | Upgrade
|
| Free Cash Flow Per Share | - | 0.97 | 0.85 | 0.20 | 0.02 | Upgrade
|
| Dividend Per Share | - | 0.300 | 0.200 | 0.160 | 0.270 | Upgrade
|
| Dividend Growth | - | 50.00% | 25.00% | -40.74% | 17.39% | Upgrade
|
| Gross Margin | 6.82% | 43.22% | 46.10% | 41.38% | 41.06% | Upgrade
|
| Operating Margin | 6.82% | 9.52% | 8.06% | 6.80% | 4.96% | Upgrade
|
| Profit Margin | 5.32% | 7.71% | 6.41% | 4.63% | 6.15% | Upgrade
|
| Free Cash Flow Margin | - | 8.67% | 7.65% | 1.84% | 0.19% | Upgrade
|
| EBITDA | 613.17 | 964.84 | 855.23 | 744.03 | 568.04 | Upgrade
|
| EBITDA Margin | 9.32% | 11.48% | 10.14% | 8.98% | 6.88% | Upgrade
|
| D&A For EBITDA | 164.66 | 164.66 | 175.4 | 180.49 | 158.86 | Upgrade
|
| EBIT | 448.51 | 800.18 | 679.83 | 563.54 | 409.19 | Upgrade
|
| EBIT Margin | 6.82% | 9.52% | 8.06% | 6.80% | 4.96% | Upgrade
|
| Effective Tax Rate | 26.10% | 19.62% | 18.27% | 19.24% | 18.70% | Upgrade
|
| Revenue as Reported | - | 8,401 | 8,430 | 8,282 | 8,254 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.